Ibandronic acid
Boniva, Bondronat, Bonviva (ibandronic acid) is a small molecule pharmaceutical. Ibandronic acid was first approved as Boniva on 1996-06-25. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, and hypercalcemia amongst others. It is known to target farnesyl pyrophosphate synthase.
| Trade Name | Bondronat, Bonviva |
|---|---|
| Common Name | Ibandronic acid |
| Indication | bone fractures, breast diseases, breast neoplasms, calcium metabolism disorders, hypercalcemia, neoplasm metastasis, neoplasms by site, neoplastic processes, postmenopausal osteoporosis, water-electrolyte imbalance, wounds and injuries |
| Drug Class | Androgens |
